Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: 31Floors who wrote (32150)	1/5/2015 1:19:13 AM
From: scouser	Respond to of 49402

COV, here is the 10yr, I do not see anything in particular that jumps out T/A wise.

To: 31Floors who wrote (32150)	1/5/2015 11:03:25 AM
From: zen_lunatic420	1 Recommendation Recommended By WorthaDeeperLook Read Replies (1) \| Respond to of 49402

COV: Molnlycke is pumping our products to the medical community. Here is a summary of the all the scientific posters presented at the Wounds UK conference. Notice that three of the five posters Molnlycke presented were presenting data about Mepitel Film AM (two of them were credited to Covalon's Chief Scientific Officer, Val DiTizio): wounds-uk.com The three posters follow: A laboratory study of the synergistic effect of chlorhexidine and silver: wounds-uk.com A human repeat patch test study: wounds-uk.com An investigation into the ability of an antimicrobial dressing with soft silicone to prevent microbial re-growth: wounds-uk.com Some posters on Stockhouse have questioned how committed Molnylcke is to selling these products, well here is some proof they are investing in building the clinical evidence to support these product sales.....AND they are out there actively promoting it! I am not expecting any huge gains in the next couple of quarterly reports that will be reported soon, but will be encouraged to see any growth over the previous record high for wound care sales of $1.41 Million, these sales will take a while to get traction, but should build a nice recurring revenue stream over the next couple of years as clinics and hospitals adopt the use of Mepitel Film AM as a best practice for infection control.